{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:08:07Z","timestamp":1790093287492,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-026-04379-6","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:43:13Z","timestamp":1771429393000},"page":"1667-1679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Transarterial Radioembolization and Transarterial Chemoembolization as Downstaging or Bridging Strategies for Hepatocellular Carcinoma Before Liver Transplantation: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Minghang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8868-367X","authenticated-orcid":false,"given":"Ye","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"6","key":"4379_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"4379_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215558","author":"L Crocetti","year":"2021","unstructured":"Crocetti L, Bozzi E, Scalise P, et al. Locoregional treatments for bridging and downstaging HCC to liver transplantation. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13215558.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4379_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"4379_CR4","first-page":"1014","volume":"63","author":"FY Yao","year":"2016","unstructured":"Yao FY, Fidelman N. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging? Hepatology. 2016;63(3):1014\u201325.","journal-title":"Hepatology"},{"issue":"13","key":"4379_CR5","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/cancers16132374","volume":"16","author":"N De Stefano","year":"2024","unstructured":"De Stefano N, Patrono D, Colli F, Rizza G, Paraluppi G, Romagnoli R. Liver transplantation for hepatocellular carcinoma in the era of immune checkpoint inhibitors. Cancers (Basel). 2024;16(13):2374.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4379_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","volume":"104","author":"N Mehta","year":"2020","unstructured":"Mehta N, Bhangui P, Yao FY, et al. Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1136\u201342.","journal-title":"Transplantation"},{"issue":"2","key":"4379_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.trre.2017.01.004","volume":"31","author":"HC Oligane","year":"2017","unstructured":"Oligane HC, Close ON, Xing M, Kim HS. Bridging locoregional therapy: longitudinal trends and outcomes in patients with hepatocellular carcinoma. Transplant Rev Orlando. 2017;31(2):136\u201343.","journal-title":"Transplant Rev Orlando"},{"issue":"6","key":"4379_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/LVT.0000000000000357","volume":"30","author":"A Arvind","year":"2024","unstructured":"Arvind A, Seif El Dahan K, Malhotra R, et al. Association between bridging therapy and posttransplant outcomes in patients with HCC within Milan criteria: a systematic review and meta-analysis. Liver Transpl. 2024;30(6):595\u2013606.","journal-title":"Liver Transpl"},{"issue":"1","key":"4379_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"1","key":"4379_CR10","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","volume":"13","author":"PA Clavien","year":"2012","unstructured":"Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13(1):e11-22.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4379_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/tri.13123","volume":"31","author":"HC Pommergaard","year":"2018","unstructured":"Pommergaard HC, Rostved AA, Adam R, et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int. 2018;31(5):531\u20139.","journal-title":"Transpl Int"},{"issue":"3","key":"4379_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2012.09.021","volume":"58","author":"M Cescon","year":"2013","unstructured":"Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58(3):609\u201318.","journal-title":"J Hepatol"},{"issue":"5","key":"4379_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","volume":"33","author":"JR Kallini","year":"2016","unstructured":"Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with Yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33(5):699\u2013714.","journal-title":"Adv Ther"},{"issue":"10","key":"4379_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","volume":"11","author":"R Salem","year":"2013","unstructured":"Salem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358-1365.e1351.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"4379_CR15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-1163.e1152.","journal-title":"Gastroenterology"},{"issue":"9","key":"4379_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"4379_CR17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805.","journal-title":"Stat Methods Med Res"},{"key":"4379_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"4379_CR19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"1","key":"4379_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40001-022-00708-w","volume":"27","author":"T Benk\u00f6","year":"2022","unstructured":"Benk\u00f6 T, K\u00f6nig J, Theysohn JM, et al. Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization? Eur J Med Res. 2022;27(1):74.","journal-title":"Eur J Med Res"},{"key":"4379_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejrad.2017.05.022","volume":"93","author":"A Gabr","year":"2017","unstructured":"Gabr A, Abouchaleh N, Ali R, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. Eur J Radiol. 2017;93:100\u20136.","journal-title":"Eur J Radiol"},{"issue":"11","key":"4379_CR22","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1245\/s10434-008-0071-3","volume":"15","author":"JT Heckman","year":"2008","unstructured":"Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol. 2008;15(11):3169\u201377.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"4379_CR23","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","volume":"9","author":"RJ Lewandowski","year":"2009","unstructured":"Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920\u20138.","journal-title":"Am J Transplant"},{"issue":"5","key":"4379_CR24","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","volume":"161","author":"N Mehta","year":"2021","unstructured":"Mehta N, Frenette C, Tabrizian P, et al. Downstaging outcomes for hepatocellular carcinoma: results from the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology. 2021;161(5):1502\u201312.","journal-title":"Gastroenterology"},{"issue":"4","key":"4379_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jvir.2023.12.009","volume":"35","author":"M Mosenthal","year":"2024","unstructured":"Mosenthal M, Adams W, Cotler S, et al. Locoregional therapies for hepatocellular carcinoma prior to liver transplant: comparative pathologic necrosis, radiologic response, and recurrence. J Vasc Interv Radiol. 2024;35(4):506\u201314.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"4379_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2214\/AJR.22.28385","volume":"220","author":"A Sarwar","year":"2023","unstructured":"Sarwar A, Bonder A, Hassan L, et al. Factors associated with complete pathologic necrosis of hepatocellular carcinoma on explant evaluation after locoregional therapy: A national analysis using the UNOS database. AJR Am J Roentgenol. 2023;220(5):727\u201335.","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"4379_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jvir.2025.05.009","volume":"36","author":"A Sher","year":"2025","unstructured":"Sher A, Todd RI, Shilo D, et al. Histopathologic response and oncologic outcomes after segmental and subsegmental transarterial chemoembolization and radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2025;36(8):1285-1295.e1282.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"4379_CR28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jvir.2023.02.016","volume":"34","author":"X Wu","year":"2023","unstructured":"Wu X, Heller M, Kwong A, Fidelman N, Mehta N. Cost-effectiveness analysis of interventional liver-directed therapies for a single, small hepatocellular carcinoma in liver transplant candidates. J Vasc Interv Radiol. 2023;34(7):1237-1246.e1233.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"4379_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/LVT.0000000000000249","volume":"30","author":"X Wu","year":"2024","unstructured":"Wu X, Kwong A, Heller M, Lokken RP, Fidelman N, Mehta N. Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant. Liver Transpl. 2024;30(2):151\u20139.","journal-title":"Liver Transpl"},{"issue":"3","key":"4379_CR30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/HEP.0000000000001231","volume":"82","author":"E Xu","year":"2025","unstructured":"Xu E, Tabrizian P, Gutierrez J, et al. Downstaging of hepatocellular carcinoma before liver transplantation: results from a national multicenter prospective cohort study. Hepatology. 2025;82(3):612\u201325.","journal-title":"Hepatology"},{"issue":"5","key":"4379_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/COC.0000000000000678","volume":"43","author":"AG Zori","year":"2020","unstructured":"Zori AG, Ismael MN, Limaye AR, et al. Locoregional therapy protocols with and without radioembolization for hepatocellular carcinoma as bridge to liver transplantation. Am J Clin Oncol. 2020;43(5):325\u201333.","journal-title":"Am J Clin Oncol"},{"key":"4379_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/JHC.S61146","volume":"3","author":"J Balogh","year":"2016","unstructured":"Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41\u201353.","journal-title":"J Hepatocell Carcinoma"},{"issue":"15","key":"4379_CR33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"7","key":"4379_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1470-2045(20)30224-2","volume":"21","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b\/3 trial. Lancet Oncol. 2020;21(7):947\u201356.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4379_CR35","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/liv.12144","volume":"33","author":"E Tsochatzis","year":"2013","unstructured":"Tsochatzis E, Garcovich M, Marelli L, et al. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver Int. 2013;33(6):944\u20139.","journal-title":"Liver Int"},{"issue":"6","key":"4379_CR36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00423-017-1609-2","volume":"402","author":"D Kollmann","year":"2017","unstructured":"Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402(6):863\u201371.","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"4379_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.29485","volume":"67","author":"L Kulik","year":"2018","unstructured":"Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67(1):381\u2013400.","journal-title":"Hepatology"},{"issue":"3","key":"4379_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L, et al. (90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE Phase II randomized controlled trial. Radiology. 2022;303(3):699\u2013710.","journal-title":"Radiology"},{"issue":"10","key":"4379_CR39","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/lt.23945","volume":"20","author":"A Goel","year":"2014","unstructured":"Goel A, Mehta N, Guy J, et al. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014;20(10):1221\u20138.","journal-title":"Liver Transpl"},{"key":"4379_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13096","author":"S Radunz","year":"2017","unstructured":"Radunz S, Saner FH, Treckmann J, et al. Hepatic artery and biliary complications in liver transplant recipients with radioembolization bridging treatment for hepatocellular carcinoma. Clin Transplant. 2017. https:\/\/doi.org\/10.1111\/ctr.13096.","journal-title":"Clin Transplant"},{"issue":"2","key":"4379_CR41","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"A El Fouly","year":"2015","unstructured":"El Fouly A, Ertle J, El Dorry A, et al. In intermediate stage hepatocellular carcinoma: Radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35(2):627\u201335.","journal-title":"Liver Int"},{"issue":"4","key":"4379_CR42","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00270-005-0171-4","volume":"29","author":"K Sato","year":"2006","unstructured":"Sato K, Lewandowski RJ, Bui JT, et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol. 2006;29(4):522\u20139.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"4379_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.adro.2015.12.003","volume":"1","author":"M Mohamed","year":"2016","unstructured":"Mohamed M, Katz AW, Tejani MA, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 2016;1(1):35\u201342.","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"4379_CR44","doi-asserted-by":"publisher","first-page":"738","DOI":"10.4254\/wjh.v7.i5.738","volume":"7","author":"C Mosconi","year":"2015","unstructured":"Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J Hepatol. 2015;7(5):738\u201352.","journal-title":"World J Hepatol"},{"issue":"1","key":"4379_CR45","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1245\/s10434-012-2513-1","volume":"20","author":"M Rodr\u00edguez-Per\u00e1lvarez","year":"2013","unstructured":"Rodr\u00edguez-Per\u00e1lvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20(1):325\u201339.","journal-title":"Ann Surg Oncol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-026-04379-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:35:18Z","timestamp":1790091318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-026-04379-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4379"],"URL":"https:\/\/doi.org\/10.1007\/s00270-026-04379-6","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}